Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020
Research

Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013–2018

Pieter P.A. Lestrade, Jochem B. Buil, Martha T. van der Beek, Ed J. Kuijper, Karin van Dijk, Greetje A. Kampinga, Bart J.A. Rijnders, Alieke G. Vonk, Sabine C. de Greeff, Annelot F. Schoffelen, Jaap van Dissel, Jacques F. Meis, Willem J.G. Melchers, Paul E. VerweijComments to Author , and Kuijper
Author affiliations: VieCuri Hospital, Venlo, the Netherlands (P.P.A. Lestrade); Center of Expertise in Mycology Radboud University Medical Center/Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands (J.B. Buil, J.F. Meis, W.J.G. Melchers, P.E. Verweij); Leiden University Medical Center, Leiden, the Netherlands (M.T. van der Beek, E.J. Kuijper); Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands (K. van Dijk); University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (G.A. Kampinga); Erasmus Medical Center, Rotterdam, the Netherlands (B.J.A. Rijnders, A.G. Vonk); Center for Infectious Disease Control, Dutch National Institute for Public Health and the Environment, Bilthoven, the Netherlands (S.C. de Greeff, A.F. Schoffelen, J. van Dissel)

Main Article

Table 1

Number of Aspergillus fumigatus culture-positive patients screened for azole resistance and azole resistance frequency in clinical A. fumigatus isolates in 5 University Medical Centers in the Netherlands*

Surveillance center No. resistant/no. screened (%)
2013 2014 2015 2016 2017 2018
Erasmus MC, Rotterdam 10/231 (4.3) 10/265 (3.8) 7/22 (31.8)† 24/186 (12.9) 19/147 (12.9) 17/129 (13.2)
LUMC, Leiden 19/99 (19.2) 15/113 (13.3) 23/141 (16.3) 18/88 (20.5) 27/114 (23.7) 25/120 (20.8)
Radboud UMC, Nijmegen 6/123 (4.9) 7/143 (4.9) 12/145 (8.3) 20/210 (9.5) 21/198 (10.6) 23/196 (11.7)
UMCG, Groningen 16/194 (8.2) 18/191 (9.4) 15/225 (6.7) 26/215 (12.1) 35/240 (14.6) 34/238 (14.3)
VUMC, Amsterdam
 8/113 (7.1)
 9/104 (8.7)
 14/89 (15.7)
 13/85 (15.3)
 12/75 (16.0)
 13/81 (16.0)
Total 58/760 (7.6) 59/814 (7.2) 64/600 (10.7)‡ 101/784 (12.9) 114/774 (14.7) 112/764 (14.7)

*MC, medical center; UMC, university medical center.
†Only a limited number of patients was screened for azole resistance.
‡Calculation of resistance frequency did not include the cases of Erasmus MC.

Main Article

Page created: May 05, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external